Published in Pharma Investments, Ventures and Law Weekly, April 2nd, 2006
"The fourth quarter concluded a transformative year for Anadys, highlighted in June 2005 by our significant collaboration agreement with Novartis for ANA975 in hepatitis C and hepatitis B and marked by continuing progress in our clinical development programs," said Kleanthis G. Xanthopoulos, PhD, Anadys' president and CEO.
"Through our partnership with Novartis, we have placed the ANA975 program on firm clinical developmental and strategic pathways. In addition, we have selected ANA773, a novel Toll-Like Receptor-7 (TLR-7)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly